A new approach to the treatment of malaria in pregnant women in West AfricaOctober 13, 2006A new approach to treatment for pregnant women suffering from malaria in west Africa has been found to be both safe and effective, following a randomised trial carried out by a team based in Ghana and at the London School of Hygiene & Tropical Medicine (LSHTM). Treating women with the drug amodiaquine, either alone or in combination with sulphadoxine-pyrimethamine (SP), was found to almost completely eliminate the malaria parasite and to cause no serious side-effects in the women being treated. The study, carried out among pregnant women who attended antenatal clinics at a district hospital in Ghana, is published in today's Lancet. The research team was based jointly at St Theresa's Hospital, Nkoranza, Ghana and at LSHTM. Malaria parasites are becoming increasingly resistant to choloroquine and sulphadoxine-pyrimethamine (SP) across Africa and there is a need to find new drugs which are safe and well tolerated. Most countries in Africa are adopting artesunate-based combination therapy (ACT) as the preferred first line treatment but there is insufficient information as to its safety of ACT during pregnancy. There are concerns that ACT might have a deleterious effect on the developing embryo, particularly when given during the first trimester of pregnancy. The extent of drug resistance is not as high in west Africa as it is in east Africa, so the authors sought to determine whether amodiaquine, which is effective in some areas with chloroquine resistance, given alone or in combination with SP might be an effective and safe treatment to use until the safety of ACT treatment in pregnancy has been be established. They screened pregnant women with a gestational age of 16 weeks or more for the malaria parasite and those who tested positive (900 women) were enrolled, and randomly treated with four different regimens. Parasitological failure by day 28 was 14%, 11%, 3% and 0% in the women assigned choloroquine, SP, amodiaquine, and amodiaquine plus SP respectively. Professor Brian Greenwood, Clinician and Epidemiologist at LSHTM, and one of the study's authors, comments: 'Malaria in pregnancy poses a threat to both the mother and the foetus. Previous studies had already found amodiaquine alone or in combination with SP to be an effective treatment of malaria in children in west Africa, but our research confirms that this is also true for pregnant women. No serious side-effects were noted and the treatment was well tolerated by the majority of women who took part in the trial'. London School of Hygiene & Tropical Medicine |
|||||||||||||||||||||
| Related Malaria Current Events and Malaria News Articles U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. DNA barcodes: Creative new uses span health, fraud, smuggling, history, more The scientific ability to quickly and accurately identify species through DNA "barcoding" is being embraced and applied by a growing legion of global authorities - from medical and agricultural researchers to police and customs authorities to palaeontologists and others. PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa. Global challenges and opportunities in fighting HIV/AIDS and neglected diseases Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs. Media availability: The role of biomedical research in malaria eradication Although malaria has been controlled in many local and regional populations, the permanent elimination of malaria parasites throughout the world remains an elusive goal, and the disease continues to claim nearly one million lives each year. Ineffective monotherapies common in high-burden malarious countries ACTwatch, a research project led by PSI, in collaboration with the London School of Hygiene and Tropical Medicine, released evidence today that indicates that artemisinin combination therapy, the most effective medicines for treating malaria, continue to have a significantly low presence on the market among populations considered to be most at risk. New tool promises more accurate antimalarial drug dosing Scientists at LSTM have developed a tool to support the development of appropriate age-based dosing regimens for malaria drugs. Cell phones become handheld tools for global development Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment. Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan. More Malaria Current Events and Malaria News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||